Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT03199651 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

BLCIO
Start date: July 17, 2017
Phase: N/A
Study type: Interventional

This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.

NCT ID: NCT03199599 Completed - Clinical trials for Non Small Cell Lung Cancer

Prognostic PET/CT Model in Non Small Cell Lung Cancer

Start date: September 1, 2016
Phase:
Study type: Observational

Prospective validation of a prognostic model based on advanced PET/CT image analysis in non small cell lung cancer

NCT ID: NCT03198923 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer

Start date: September 13, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based immunotherapy in subjects with non small cell lung cancer.

NCT ID: NCT03198468 Completed - Lung Cancer Clinical Trials

Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)

VAPORIZE
Start date: November 21, 2018
Phase: N/A
Study type: Interventional

This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment. Patients will receive BTVA-C treatment followed by standard-of-practice surgical resection.

NCT ID: NCT03198117 Terminated - Clinical trials for Non-small Cell Lung Cancer

Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)

Start date: April 25, 2017
Phase: N/A
Study type: Interventional

This study including two parts,one part is a randomized clinical trial design,another part is a registration study.

NCT ID: NCT03198052 Recruiting - Cancer Clinical Trials

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers

Start date: July 1, 2017
Phase: Phase 1
Study type: Interventional

The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR -CAR-T cell immunotherapy on human cancers will firstly be tested.

NCT ID: NCT03197467 Completed - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

NEOMUN
Start date: June 18, 2018
Phase: Phase 2
Study type: Interventional

NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage II/IIIA suitable for curative intent surgery.

NCT ID: NCT03196986 Completed - Clinical trials for Non-small Cell Lung Cancer

mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Start date: August 15, 2017
Phase: Phase 3
Study type: Interventional

This randomized, double-blind, multi-center phase 3 study is aimed to compare the efficacy and safety of mil60 with bevacizumab as first-line treatment when combined with standard chemotherapy (paclitaxel/carboplatin) in treatment-naive patients with advanced or recurrent non-squamous NSCLC.

NCT ID: NCT03195569 Recruiting - Clinical trials for Non Small Cell Lung Cancer

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Start date: March 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the study of QL1101 and Avastin® in patients with Non-squamous Non-small Cell Lung Cancer

NCT ID: NCT03195491 Completed - Lung Cancer Clinical Trials

A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

CheckMate870
Start date: December 25, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.